anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
HYPOTHESIS: The overarching hypothesis is that the average layperson lacks sufficient knowledge about the aggressive life support measures used routinely in contemporary Critical Care to make informed decisions for themselves and their loved ones. Considering that most Canadians have not even heard of the term Advance Care Planning, it is likely that there is a gap in their knowledge and expectations of Critical Care. Such a gap can be bridged through education - the only caveat being that the individual should be in full possession of their faculties and can make informed decisions. This point is critical.

Thus this study uses a mixed methods (qualitative and quantitative) research design to address the following questions: 1) What is the state of knowledge about Critical Care interventions among healthy elderly laypersons in London, Ontario? 2) What are the barriers to formulating ACPs? 3) What opportunities exist for increasing ACP in the healthy elderly population? The primary objective of this proposal is to assess public knowledge of Critical Care interventions (and their outcomes) from the perspective of making Advance Care Plans. Secondary Objectives are 1) To evaluate local barriers to Advance Care Planning 2) To determine effective modes of education for Advance Care Planning that could be used for the community and in our hospital setting.
Cytochromes P450 (CYPs) play a prominent role in catalyzing phase I xenobiotic biotransformation and account for about 75% of the total metabolism of commercially available drugs, including chemotherapeutics. The gene expression and enzyme activity of CYPs are variable between individuals, which subsequently leads to different patterns of susceptibility to carcinogenesis by genotoxic xenobiotics, as well as differences in the efficacy and toxicity of clinically used drugs. This research aimed to examine the presence of the CYP2B6*9 polymorphism and its possible association with the incidence of B-CLL in Egyptian patients, as well as the clinical outcome after receiving cyclophosphamide chemotherapy. DNA was isolated from whole blood samples of 100 de novo B-CLL cases and also from 100 sex- and age-matched healthy individuals. The presence of the CYP2B6*9 (G516T) polymorphism was examined by PCR-based allele specific amplification (ASA). Patients were further indicated for receiving chemotherapy, and then they were followed up. The CYP2B6*9 variant indicated a statistically significant higher risk of B-CLL under different genetic models, comprising allelic (T-allele vs. G-allele, OR = 4.8, p < 0.001) and dominant (GT + TT vs. GG, OR = 5.4, p < 0.001) models. Following cyclophosphamide chemotherapy, we found that the patients with variant genotypes (GT + TT) were less likely to achieve remission compared to those with the wild-type genotype (GG), with a response percentage of (37.5% vs. 83%, respectively). In conclusion, our findings showed that the CYP2B6*9 (G516T) polymorphism is associated with B-CLL susceptibility among Egyptian patients. This variant greatly affected the clinical outcome and can serve as a good therapeutic marker in predicting response to cyclophosphamide treatment.
Transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC) can increase endurance time in lower body tasks. Therefore, the purpose of this study is to examine the effect of DLPFC-tDCS on the time to task failure (TTF) of a fatiguing contraction performed by hand muscles. The study will use a double-blind, randomized, SHAM-controlled, crossover design with each participant performing two experimental sessions held 3-7 days apart. The only difference between the two sessions will be the type of stimulation (tDCS or SHAM; counterbalanced) applied concurrent with the fatiguing contraction. The fatiguing contraction will involve gripping a manipulandum with the index finger and thumb. This will be accomplished by using a precision grip and matching an isometric target equal to 15% of the maximum voluntary contraction (MVC) for as long as possible until task failure.
1284544 Agglomerated materials COLGATEPALMOLIVE CO 4 Aug 1969 [5 Aug 1968 (2)] 38954/69 Heading C1A An agglomerated material e.g. dicalcium phosphate, sodium metaphosphate, calcium carbonate, hydrated alumina, zirconium silicate or various other phosphates, MgCO 3 , SiO 2 , aluminium silicate or polymethyl methacrylate, which material is suitable for use as a toothpaste ingredient, comprises water-insoluble dental polishing, particles of the agglomerated material being visible to the naked eye (preferably of size less than 2380 microns) and palpable and substantially retaining their identity in the toothpaste and in the presence of saliva but being easily reducible by toothbrushing to individual particles of polishing agent each of which is fine, impalpable and invisible to the naked eye. The polishing agent is blended with a binding agent e.g. polyethylene glycol, gum acacia, or polyvinyl pyrrolidone. The blend of polishing agent and binding agent or with a tabletting agent may be compressed into tablets which are then broken down into the agglomerated particles. The agglomerates may be coloured by a dye or pigment and may be incorporated into translucent or transparent gel type toothpastes or into opaque toothpastes as described in Specifications 1,284,546 and 1,284,545 (see Division A5).
Carcinogenicity studies were performed in mice and rats. No carcinogenic potential was identified in either species. Vismodegib was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay and was not clastogenic in the in vitro human chromosomal aberration assay in human peripheral blood lymphocytes or in the in vivo rat bone marrow micronucleus assay.

In a dedicated 26-week rat fertility study, no effects on male reproductive organs or fertility endpoints were observed at vismodegib doses of 100 mg/kg/day [approximately 1.3 times the human exposure (steady state AUC0-24hr) at the 150 mg clinical dose] either at the end of dosing or following a 16-week recovery phase. While there were increased numbers of degenerating germ cells and hypospermia in sexually immature dogs observed at ≥ 50 mg/kg/day in the 4-week general toxicity study, there were no effects on male reproductive organs in sexually mature rats and dogs, in the vismodegib general toxicity studies of up to 26-weeks.

In a female fertility study, treatment of rats with vismodegib at 100 mg/kg/day [approximately 1.2-times the human exposure (steady state AUC0-24hr) at the 150 mg clinical dose] for 26-weeks prior to mating resulted in decreased implantations, increased percent preimplantation loss, and decreased numbers of dams with viable embryos. No vismodegib-related changes in fertility were observed following a 16-week recovery period. In a 26-week general toxicity study in rats, decreased numbers of corpora lutea were observed at 100 mg/kg/day; the effect was not reversed by the end of an 8-week recovery period.
HSCs, the resident pericytes of the liver, have consistently been at the forefront of liver research due to their crucial roles in various hepatic pathological processes. Prior literature often depicted HSCs in a binary framework, categorizing them as either quiescent or activated. However, recent advances in HSC research, particularly the advent of single-cell RNA-sequencing, have revolutionized our understanding of these cells. This sophisticated technique offers an unparalleled, high-resolution insight into HSC populations, uncovering a spectrum of diversity and functional heterogeneity across various physiological states of the liver, ranging from liver development to the liver aging process. The single-cell RNA-sequencing revelations have also highlighted the intrinsic plasticity of HSCs and underscored their complex roles in a myriad of pathophysiological processes, including liver injury, repair, and carcinogenesis. This review aims to integrate and clarify these recent discoveries, focusing on how the inherent plasticity of HSCs is central to their dynamic roles both in maintaining liver homeostasis and orchestrating responses to liver injury. Future research will clarify whether findings from rodent models can be translated to human livers and guide how these insights are harnessed to develop targeted therapeutic interventions.
Patients ingest OpenBiome FMT Capsule Dose Extended (DE) orally for two consecutive days. One dose is equivalent to the ingestion of 30 capsules and thus each day the patient will ingest 15 capsules. If no response is noted after 7 days, patients may receive a second dose of FMT for an additional 2 days.
The 10 gram Pharmacy Bulk Package should be penetrated ONLY ONE TIME utilizing a suitable sterile transfer device or dispensing set and should be reconstituted with 47 mL of diluent for an approximate concentration of 200 mg/mL (withdrawable volume 52 mL) or 97 mL of diluent for an approximate concentration of 100 mg/mL withdrawable volume 102 mL), in a suitable work area such as a laminar flow hood, using aseptic technique. Shake to dissolve; inspect for particulate matter and discoloration prior to use. Stock solutions may be further diluted for IV infusion with diluents as listed in COMPATIBILITY AND STABILITY section. The reconstituted content of the 10 g Pharmacy Bulk Package should be withdrawn immediately, using a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents. However, if it is not possible, aliquoting operations must be completed within four hours of reconstitution. Discard the reconstituted stock solution 4 hours after initial entry. Solutions of cefotaxime range from very pale yellow to light amber, depending on concentration, diluent used, and length and condition of storage.

NOTE: Solutions of cefotaxime must not be admixed with aminoglycoside solutions. If cefotaxime and aminoglycosides are to be administered to the same patient, they must be administered separately and not as mixed injection.

A SOLUTION OF 1 G CEFOTAXIME IN 14 ML OF STERILE WATER FOR INJECTION IS ISOTONIC.

IV Administration: The IV route is preferable for patients with bacteremia, bacterial septicemia, peritonitis, meningitis, or other severe or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or impending.

For intermittent IV administration, a solution containing 1 gram or 2 grams in 10 mL of Sterile Water for Injection can be injected over a period of three to five minutes. Cefotaxime should not be administered over a period of less than three minutes. (See WARNINGS). With an infusion system, it may also be given over a longer period of time through the tubing system by which the patient may be receiving other IV solutions. However, during infusion of the solution containing cefotaxime, it is advisable to discontinue temporarily the administration of other solutions at the same site.

For the administration of higher doses by continuous IV infusion, a solution of cefotaxime may be added to IV bottles containing the solutions discussed below.
The efficacy of citalopram hydrobromide as a treatment for major depressive disorder was established in two placebo-controlled studies (of 4 to 6 weeks duration) in adult outpatients (ages 18-66) meeting DSM-III or DSM-III-R criteria for major depressive disorder (MDD) (Studies 1 and 2). 

Study 1, a 6-week trial in which patients received fixed citalopram hydrobromide doses of 10 mg, 20 mg, 40 mg, and 60 mg daily, showed that citalopram hydrobromide 40 daily and 60 mg daily (1.5 times the maximum recommended daily dosage) was effective as measured by the Hamilton Depression Rating Scale (HAMD) total score, the primary efficacy endpoint. The HAMD-17 is a 17-item, clinician-rated scale used to assess severity of depressive symptoms. Scores on the HAMD-17 range from 0 to 52, with higher scores indicating more severe depression. This study showed no clear effect of the 10 mg and 20 mg daily doses, and the 60 mg daily dose was not more effective than the 40 mg daily dose. Due to the risk of QTc prolongation and ventricular arrhythmias, the maximum recommended dosage of citalopram hydrobromide is 40 mg once daily.  


In study 2, a 4-week, placebo-controlled trial in patients with MDD, the initial dose was 20 mg daily, followed by titration to the maximum tolerated dose or a maximum dose of 80 mg daily (2 times the maximum recommended daily dosage). Patients treated with citalopram hydrobromide showed statistically significantly greater improvement than placebo patients on the HAMD total score, the primary efficacy endpoint. In three additional placebo-controlled trials in patients with MDD, the difference in response to treatment between patients receiving citalopram hydrobromide and patients receiving placebo was not statistically significant.  


In two long-term studies, patients with MDD who had responded to citalopram hydrobromide during an initial 6 or 8 weeks of acute treatment were randomized to continuation of citalopram hydrobromide or placebo. In one study, patients received fixed doses of citalopram hydrobromide 20 mg or 40 mg daily and in the second study, patients received flexible doses of citalopram hydrobromide 20 mg daily to 60 mg daily (1.5 times the maximum recommended daily dosage). In both studies, patients receiving continued citalopram hydrobromide treatment experienced statistically significantly lower relapse rates over the subsequent 6 months compared to those receiving placebo. In the fixed-dose study, the decreased rate of depression relapse was similar in patients receiving 20 mg or 40 mg daily of citalopram hydrobromide. Due to the risk of QTc prolongation and ventricular arrhythmias, the maximum recommended dosage of citalopram hydrobromide is 40 mg once daily.  


Analyses of the relationship between treatment outcome and age, gender, and race did not suggest any differential responsiveness on the basis of these patient characteristics.
The invention relates to a method for producing moulded bodies by means of injection moulding, comprising the following steps: a) a (meth)acrylate copolymer, consisting of between 85 and 98 wt. % of radically polymerised C1 to C4 alkyl esters of the acrylic or methacrylic acid and between 15 and 2 wt. % of (meth)acrylate monomers having a quaternary ammonium group in the alkyl radical, is melted and mixed with between 10 and 25 wt. % of a plasticizer, between 10 and 50 wt. % of an anti-adhesive agent, and/or between 0.1 and 3 wt. % of a parting agent, and optionally other pharmaceutically standard additives or auxiliary agents and/or a pharmaceutical active ingredient; b) the mixture is degassed at temperatures of at least 120 °C, whereby the content of low-boiling constituents is reduced to, at the highest, 0.5 wt. %, with a steam pressure of at least 1.9 bar at 120 °C; and c) the degassed mixture is injected at a temperature of between 80 and 160 °C in the mould of an injection moulding unit and the moulded body obtained is removed from the mould.
The invention provides pharmaceutical compositions for topical administration in treating vaginal infections, e.g. vaginitis. Such compositions comprise: W at least one triazole compound active against Candida albicans, preferably at least one such compound which is additionally active against one or more non- albicans Candida species, and (ii) at least one additional anti-vaginitis medicament, preferably an anti-fungal, anti-protozoal and/or anti-bacterial agent. Preferred compositions include as active agents is terconazole in combination with tinidazole and/or tioconazole. In a further aspect the compositions in accordance with the invention also include a bioadhesive agent, e.g. a mucoadhesive, to promote adhesion to the vaginal mucosa. The use of a bioadhesive may also provide for controlled, e.g. rapid and/or delayed (sustained), release of the active agents.
PROBLEM TO BE SOLVED: To obtain a therapeutic agent free from any side effect and intended for effectively treating the dermatoses in carnivorous animals developing due to fungal/bacterial infection or parasites by including vitamin C and/or zinc as active ingredient(s). SOLUTION: This therapeutic agent is obtained by including (A) vitamin C and/or (B) zinc as active ingredient(s), being pref. in the form of an agent for internal or external use. The daily dose of this agent is pref. 0.2-2,000 mg/kg and 0.001-100 mg/kg, more pref. 100-1,000 mg/kg and 0.01-1 mg/kg, for the ingredients A and B, respectively.
PURPOSE:To provide the subject preventive and therapeutic agent containing a taurine dipeptide or its salt as the active component and having an affect on heart diseases such as ischemic heart disease, myocardial disorders in ischemic state, e.g. during a cardiac operation, heart failure or angina. CONSTITUTION:A medicine for heart diseases containing one or more compounds selected from e.g. glycyltaurine or alanyltaurine of the formula (R is amino acid residue) and pharmaceutically permissible salts (e.g. acid adduct salts or metallic salts) thereof as the active components. Complex compounds between Zn, Ni, Co, Cu, Fe, etc., are included in the compounds of the formula and, in case of existence of optically active isomers, all the isomers are also included. Compounds of the formula have an effect on protecting myocardium and an enhancing action on the same. The compounds also reduce the lowering in amplitude of myocardial pulsation in a low Ca state and normalize functions of myocardium.
A Disintegrin And Metalloproteinase domain-containing protein 10 (ADAM10), is involved in several metabolic and inflammatory pathways. We speculated that ADAM10 plays a modulatory role in adipose tissue inflammation and metabolism. To this end, we studied adipose tissue-specific ADAM10 knock-out mice (aKO). While young, regular chow diet-fed aKO mice showed increased insulin sensitivity, following prolonged (33 weeks) high-fat diet (HFD) exposure, aKO mice developed obesity and insulin resistance. Compared to controls, aKO mice showed less inflammatory adipokine profile despite the significant increase in adiposity. In brown adipose tissue, aKO mice on HFD had changes in CD8+ T cell populations indicating a lesser inflammatory pattern. Following HFD, both aKO and control littermates demonstrated decreased adipose tissue pro-inflammatory macrophages, and increased anti-inflammatory accumulation, without differences between the genotypes. Collectively, our observations indicate that selective deletion of ADAM10 in adipocytes results in a mitigated inflammatory response, leading to increased insulin sensitivity in young mice fed with regular diet. This state of insulin sensitivity, following prolonged HFD, facilitates energy storage resulting in increased fat accumulation which ultimately leads to the development of a phenotype of obesity and insulin resistance. In conclusion, the data indicate that ADAM10 has a modulatory effect of inflammation and whole-body energy metabolism.
Subjects who were part of study 200622 and were randomized to receive either placebo or mepolizumab will be enrolled in this study as per study eligibility criteria. In this study, subjects will receive 300 mg of mepolizumab SC (three 100 mg SC injections) every 4 Weeks for a total of 5 doses during 20-Week treatment period.
700 MSM will be recruited through social media operated by gay organizations in China. Eligible participants will be born biologically male, age 16 years or older, report previous anal sex with another man, and reside in China. Men self-reporting previous HBV vaccination, HBV testing, or HCV testing will be excluded. After completing a baseline online survey, participants will be randomly assigned to intervention or control arms with a 1:1 allocation ratio. The intervention will include two components: (1) a multimedia component will deliver two videos and two images promoting HBV and HCV testing developed through a crowdsourcing contest in China. (2) A participatory component will invite men to submit suggestions for how to improve crowdsourced videos and images. The control arm will not view any images or videos and will not be invited to submit suggestions. All participants will be offered reimbursement for HBV and HCV testing costs. The primary outcome is HBV and HCV test uptake confirmed through electronic submission of test report photos within four weeks of enrollment. Secondary outcomes include self-reported HBV and HCV test uptake, HBV vaccination uptake, and change in stigma toward people living with HBV measured through a follow-up survey after four weeks. Men with primary and secondary outcomes will be calculated using intention to treat and as-exposed analyses and compared using two-sided 95% confidence intervals.
PROBLEM TO BE SOLVED: To make biocompatible, strong, less irregular in strength and manipulatable at the time of grinding by containing calcium titanate fibers as a base material in a calcium phosphate cement composition for organisms. SOLUTION: The calcium phosphate cement composition for organisms is formed of a base material whose main component is calcium phosphate and a miscible solvent. And furthermore calcium titanate fibers are mixed as a base material. Calcium phosphate used as a main component of the base material is not limited as long as it reacts at the presence of water or a pseudo liquid, and produces and hardens hydroxyapatite. The calcium titanate fibers are preferably fine fibers 0.1 to 100 μm in average length, 0.01 to 10 μm in average diameter, and 3 to 50 in aspect ratio. The miscible solvent is one to grind a base material and generally water or ion-exchanged water.
Use of 5% P-I from bottle dropper to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.